ORMP - NASDAQ

Oramed Pharmaceuticals Inc.

ORMP·NASDAQ

$3.65

-1.6%

HealthcareBiotechnology

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$149.38M

EPS1.5300

P/E Ratio2.39

Earnings Date06/03/2026

230.86M

Assets

49%

3Y+43.0%

5Y+417.0%

10Y+439.0%

31.12M

Total Liabilities

213%

3Y+197.0%

5Y+165.0%

10Y+87.0%

199.74M

Total Equity

37%

3Y+32.0%

5Y+508.0%

10Y+663.0%

Oramed Pharmaceuticals Inc. Funding & Solvency Profile

ORMP · NASDAQ

Current Assets

Cash & Cash Equivalents45.95M

Net Receivables4.64M

Inventory0.00

Other Current Assets2.74M

Total Current Assets133 M

Non-Current Assets

Property, Plant & Equipment1.34M

Goodwill & Intangible Assets0.00

Long-Term Investments93.74M

Other Non-Current Assets2.52M

Total Non-Current Assets98 M

Total Assets

230.86M

Financial Health Analysis

Current Ratio

6.98x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.16x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

114 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

58% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Oramed Pharmaceuticals Inc. Balance Sheet

ORMP • NASDAQ

Oramed Pharmaceuticals Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Aug 2021	Aug 2020	Aug 2019	Aug 2018	Aug 2017	Aug 2016	Aug 2015	Aug 2014	Aug 2013	Aug 2012	Aug 2011	Aug 2010	Aug 2009	Aug 2008	Aug 2007	Aug 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	45.9M	54.4M	9.1M	40.5M	77.2M	19.3M	3.3M	5M	4M	3.9M	3.2M	1.8M	2.3M	4.4M	1.5M	1.2M	1.7M	2.3M	1.9M	176.2K
Short-Term Investments	79.9M	87.5M	153M	115.3M	16.9M	20.6M	29M	25.5M	16.2M	27.1M	14M	19.5M	6.2M	200.3K	384.6K	100K	1M	2.7M	0.0	0.0
Cash & Short-Term Investments	125.9M	141.9M	162M	155.7M	94.1M	39.9M	32.3M	30.5M	20.1M	31M	17.2M	21.3M	8.5M	4.6M	1.9M	1.3M	2.7M	5M	1.9M	176.2K
Net Receivables	4.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	408K	62.9K	88.1K	567.1K	71.6K	437.3K	0.0	0.0	0.0
Accounts Receivables	4.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.9K	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	408K	62.9K	88.1K	567.1K	71.6K	400.4K	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16K	16K	18.3K	17.7K	17.9K	0.0	0.0	0.0	0.0
Other Current Assets	2.7M	1.3M	537K	1.4M	1.2M	611K	1M	574K	159K	198K	127K	64K	90.1K	539K	1.8M	7.7K	20.1K	402.6K	12K	0.0
Total Current Assets	133.3M	143.2M	162.6M	157.1M	95.3M	40.5M	33.3M	31M	20.3M	31.2M	17.4M	21.8M	8.6M	5.3M	4.3M	1.4M	3.2M	5.4M	1.9M	176.2K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.3M	1.1M	1.6M	1.8M	932K	174K	24K	17K	18K	16K	11K	14K	5.8K	4.8K	17.4K	43.5K	75.4K	98.3K	2K	0.0
Long-Term Investments	93.7M	10.9M	56.4M	2.7M	6.7M	3.9M	1.3M	16.3M	18.4M	11.6M	9M	0.0	4.6K	8.9K	10.2K	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	130.7K	0.0	0.0
Other Non-Current Assets	2.5M	34K	34K	24K	25M	20K	20K	17K	15K	15K	13K	10K	5.5K	4.7K	14.3K	10.6K	12.2K	-119.8K	5K	0.0
Total Non-Current Assets	97.6M	12.1M	58M	4.5M	32.7M	4.1M	1.3M	16.4M	18.4M	11.6M	9M	24K	15.9K	18.4K	41.9K	54.1K	87.5K	109.1K	7K	0.0
Total Assets	230.9M	155.3M	220.6M	161.6M	128M	44.6M	34.7M	47.4M	38.7M	42.8M	26.4M	21.8M	8.7M	5.3M	4.3M	1.5M	3.3M	5.5M	1.9M	176.2K
LIABILITIES
CURRENT LIABILITIES
Total Payables	15M	4.3M	551K	2.2M	2.6M	594K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Payable	443K	789K	551K	2.2M	2.6M	594K	1.3M	1.1M	571K	1.4M	953K	926K	439.5K	47.3K	47.3K	47.3K	47.3K	914K	341K	53.7K
Other Payables	14.5M	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	2.5M	1.1M	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	0.0	0.0	51M	247K	130K	44K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	275K	0.0
Capital Lease Obligations (Current)	285K	216K	267K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	1.4M	0.0	0.0	1.3M	2.7M	2.7M	2.7M	2.4M	2.4M	2.2M	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	0.0	0.0	325K	-191K	-1.4M	601K	1.3M	969K	2.1M	48K	36K	47K	58.7K	597.2K	394K	411.3K	321.3K	0.0	808K	555.3K
Total Current Liabilities	19.1M	5.7M	53.2M	5.7M	6.7M	4.5M	5.3M	4.6M	5.2M	3.6M	1.5M	973K	498.2K	644.4K	441.3K	458.6K	368.6K	914K	1.4M	608.9K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	647K	403K	31K	-5.6M	-7.8M	18K	14K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	3.3M	4M	4M	4M	4.2M	6.9M	9.7M	11.4M	13.8M	12.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	7.9M	0.0	0.0	11K	11K	11K	11K	11K	11K	11K	26K	27K	23.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	314K	90K	102K	82K	145K	229K	5.9M	8.1M	443K	390K	11K	9K	8K	872.4K	160.7K	162K	147.1K	0.0	0.0	0.0
Total Non-Current Liabilities	12M	4.2M	4.4M	4.7M	4.8M	7.2M	10M	11.7M	14.3M	13M	37K	36K	31.2K	872.4K	160.7K	162K	147.1K	914K	616K	53.7K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-914K	-616K	-53.7K
Capital Lease Obligations	825K	372K	609K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	31.1M	9.9M	57.7M	10.5M	11.5M	11.8M	15.3M	16.3M	19.5M	16.6M	1.5M	1M	529.4K	1.5M	602K	620.6K	515.7K	914K	1.4M	608.9K
SHAREHOLDERS' EQUITY
Common Stock	472K	480K	485K	476K	424K	284K	208K	207K	163K	157K	138K	121K	95.2K	80.1K	70.1K	57.6K	56.5K	56.3K	45K	41.5K
Additional Paid-In Capital	322.7M	322.4M	320.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-123.4M	-176.6M	-157.6M	-163.1M	-114.9M	-92.6M	-81.1M	-69.2M	-56.5M	-46M	-35.1M	-27.8M	-22.1M	-17.9M	-14.5M	-13M	-10M	-7.2M	-4.5M	-1.2M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	702K	401K	106K	558K	452K	303.4K	-120.8K	-106.1K	-77.8K	-45.9K	-15.5K	0.0	-16.0
Other Total Stockholders' Equity	0.0	0.0	0.0	314.4M	230.2M	125.2M	100.3M	99.4M	75.2M	71.9M	59.2M	48M	29.9M	21.7M	18.3M	13.8M	12.7M	11.8M	4.9M	768.7K
Total Stockholders' Equity	199.7M	146.3M	163.8M	151.8M	115.8M	32.9M	19.4M	31.1M	19.2M	26.2M	24.8M	20.8M	8.1M	3.8M	3.7M	830.3K	2.7M	4.6M	513K	-432.7K
Total Equity	199.7M	145.3M	162.9M	151.2M	116.5M	32.9M	19.4M	31.1M	19.2M	26.2M	24.8M	20.8M	8.1M	3.8M	3.7M	830.3K	2.7M	4.6M	513K	-432.7K
Minority Interest	0.0	-918K	-928K	-656K	744K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	230.9M	155.3M	220.6M	161.6M	128M	44.6M	34.7M	47.4M	38.7M	42.8M	26.4M	21.8M	8.7M	5.3M	4.3M	1.5M	3.3M	5.5M	1.9M	176.2K
Total Investments	173.7M	98.4M	209.4M	118M	23.6M	24.5M	30.2M	41.8M	34.5M	38.7M	23M	19.5M	6.2M	209.2K	394.8K	100K	1M	2.7M	0.0	0.0
Total Debt	825K	372K	51.6M	894K	533K	75K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	275K	0.0
Net Debt	-45.1M	-54M	42.6M	-39.6M	-76.7M	-19.2M	-3.3M	-5M	-4M	-3.9M	-3.2M	-1.8M	-2.3M	-4.4M	-1.5M	-1.2M	-1.7M	-2.3M	-1.6M	-176.2K
Shares Outstanding	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326	40,816,326

SEC Filings

ORMP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 19, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 20, 2026	February 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 14, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 31, 2025	December 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 31, 2025	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 17, 2025	November 16, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 17, 2025	November 17, 2025	2025	View Filing

Showing 1 to 10 of 366 filings

Related Guides

Blog Categories

Continue your ORMP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.